To evaluate the potential response of STAD patients to immunotherapy, we examined several key immune checkpoint targets (PDCD1, CD274, and PDCD1LG2) and compared their expression levels between the two subtypes. Here, PDCD1LG2 is linked to gastric adenocarcinoma.